Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Pfizer antes up on the feds' vaccine criticism, saying Warp Speed has everything it's asked for—and more
Federal guidance enables employers to mandate workers get COVID-19 vaccine
After Lilly's failure, NIH tests GSK/Vir and Brii COVID-19 drugs in hospitalized patients
From weaponized AI to threats against the vaccine rollout, here are 6 cybersecurity trends to watch in 2021
Healthcare roundup: CVS, Walgreens begin distributing vaccine in long-term care facilities
Biopharma roundup: Pfizer, Moderna's EU shot prices revealed; GSK, Vir and Brii tapped for new NIH antibody trials
Mesoblast craters as Novartis-backed COVID-19 drug flunks trial
Philips puts down $2.8B for BioTelemetry and its wearable heart monitors

Featured Story

Pfizer antes up on the feds' vaccine criticism, saying Warp Speed has everything it's asked for—and more

By Fraiser Kansteiner

After federal officials took aim at Pfizer's pandemic vaccine work Wednesday, Pfizer hit back. The drugmaker said its manufacturing is right on track, delivery commitments have been met and, what's more, it has millions more doses on warehouse shelves. All it needs are shipping instructions from the feds.

Federal guidance enables employers to mandate workers get COVID-19 vaccine

By Robert King

New federal guidance gives employers the authority to mandate workers take COVID-19 vaccines as hospital workers become the first to get precious few doses.

After Lilly's failure, NIH tests GSK/Vir and Brii COVID-19 drugs in hospitalized patients

By Phil Taylor

The NIH has started dosing patients in new trials of antibodies from GlaxoSmithKline/Vir Biotechnology and Brii Biosciences in patients hospitalized with COVID-19—hoping to succeed where Eli Lilly’s LY-CoV555 failed a few weeks ago.

From weaponized AI to threats against the vaccine rollout, here are 6 cybersecurity trends to watch in 2021

By Heather Landi

Could 2021 be the year that healthcare finally gets smart about cybersecurity? Many in the industry say real change needs to happen as the situation has become a matter of life and death. Here are six threats and trends to watch in 2021.

Healthcare roundup: CVS, Walgreens begin distributing vaccine in long-term care facilities

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: Pfizer, Moderna's EU shot prices revealed; GSK, Vir and Brii tapped for new NIH antibody trials

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

A Belgian official divulged the EU price tags for Pfizer and Moderna's shots. The NIH launched a trial of GSK and Vir's antibody, plus an antibody combo from Brii. The FDA cleared a home version of Abbott's rapid antigen test. COVAX secured some 2 billion vaccine doses. And Vice Pres. Pence got vaccinated on television.

Mesoblast craters as Novartis-backed COVID-19 drug flunks trial

By Phil Taylor

Australian biotech Mesoblast has been riding high on expectations for its COVID-19 treatment, licensed to Novartis, but fell back to Earth after it said a phase 3 trial of the cell therapy was a bust.

Philips puts down $2.8B for BioTelemetry and its wearable heart monitors

By Conor Hale

Philips aims to broaden the reach of its digital patient monitoring platforms, from inside the hospital out to the home, through a $2.8 billion acquisition deal for BioTelemetry and its wearable heart-tracking devices.

COVID-19 Tracker